Global Utilization And Registry Database for Improved heArt preservatioN
Launched by PARAGONIX TECHNOLOGIES · Oct 24, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study is a registry study collecting data both retrospectively from patients already transplanted and prospectively from consecutively enrolled patients for heart transplantation. The study is a chart review study.
Ongoing eligible recipients will undergo heart transplantation according to standard practices at each participating institution.
This study will be conducted at an estimated 25 institutions globally and will have about up to 3000 patients. Subjects will be followed from transplant through one-year post-transplantation (i.e., 24 hours post-transplant, discharge, 30-days, 1...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Donor and donor hearts matched to the prospective recipient based upon institutional medical practice
- • Registered male or female primary heart transplant candidates including pediatric candidates
- Exclusion Criteria:
- • Donor and donor hearts that do not meet institutional clinical requirements for transplantation
- • When safe connection with the aorta cannot be made, e.g., due to lack of enough length of the aortic root
- • Patients who are incarcerated persons (prisoners)
- • Patients who have had a previous organ transplant
About Paragonix Technologies
Paragonix Technologies is a pioneering medical device company specializing in advanced organ preservation solutions to enhance transplant outcomes. With a focus on innovative technologies, Paragonix develops cutting-edge systems that ensure the safe and efficient transport of donor organs, thereby improving the viability and success rates of transplants. Committed to transforming the field of transplantation, the company collaborates with healthcare professionals and institutions to deliver products that address critical challenges in organ preservation and transportation, ultimately aiming to save lives and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Durham, North Carolina, United States
Stanford, California, United States
Jacksonville, Florida, United States
Dallas, Texas, United States
Orlando, Florida, United States
Grand Rapids, Michigan, United States
Boston, Massachusetts, United States
Cincinnati, Ohio, United States
Graz, , Austria
Vienna, , Austria
Boston, Massachusetts, United States
Valladolid, , Spain
Madrid, , Spain
Memphis, Tennessee, United States
Washington, District Of Columbia, United States
Fort Wayne, Indiana, United States
Gainesville, Florida, United States
Norfolk, Virginia, United States
Lawrence, Kansas, United States
New York, New York, United States
State College, Pennsylvania, United States
Manchester, , United Kingdom
Washington Dc, District Of Columbia, United States
Patients applied
Trial Officials
Andreas Zuckermann, MD
Principal Investigator
ALLGEMEINES KRANKENHAUS WIEN
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials